Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IOVA with free AI briefings, catalyst countdowns, and dilution alerts.

IOVA · Iovance Biotherapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$397.5M Cash on Hand
36.5mo Cash Runway
15.1% Short Interest
$14.5 Analyst Target (10)
Follow IOVA by email Get an email when IOVA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IOVA, unsubscribe in one click. Privacy

📣 What IOVA Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tumor Infiltrating Lymphocyte Cervical Cancer Phase 2 · NCT05686226 Recruiting
Administration of Lymphodepletion Metastatic Melanoma N/A · NCT01701674 Completed
Fludarabine Phosphate Metastatic Melanoma N/A · NCT01701674 Completed
Cyclophosphamide Metastatic Melanoma N/A · NCT01701674 Completed
Lifileucel (LN-144) Metastatic Melanoma Phase 3 · NCT05727904 Recruiting
Modified Aldesleukin/Palivizumab Fusion Protein… Unresectable Melanoma Phase 1/2 · NCT06940739 Recruiting
Tumor infiltrating lymphocytes (TIL) LN-145 Metastatic Triple Negative Breast Cancer Phase 2 · NCT04111510 Completed
Autologous PD-1-knockout Tumor-infiltrating… Unresectable Melanoma Phase 1/2 · NCT05361174 Recruiting
IOV-5001 Advanced Solid Tumors Phase 1/2 · NCT07743723 Not yet recruiting
Autologous Tumor Infiltrating Lymphocytes LN-145 Cutaneous Squamous Cell Carcinoma Phase 2 · NCT07288073 Recruiting
Autologous Tumor Infiltrating Lymphocytes… Metastatic Melanoma Phase 2 · NCT03645928 Terminated
Nab-paclitaxel Metastatic Melanoma Phase 2 · NCT03645928 Terminated
Autologous Tumor Infiltrating Lymphocytes… Malignant Solid Neoplasm Phase 2 · NCT03610490 Terminated
Fludarabine Cutaneous Squamous Cell Carcinoma Phase 2 · NCT07288073 Recruiting
Autologous Peripheral Blood Lymphocytes from… Chronic Lymphocytic Leukemia Phase 1 · NCT04155710 Completed
Alpha-1-Antichymotrypsin Malignant Pleural Effusion Phase 1 · NCT07192900 Recruiting

Also used in these trials (approved or third-party drugs, not IOVA's own candidates): Pembrolizumab, Ipilimumab, Nivolumab, Nivolumab And Relatlimab-Rmbw, Paclitaxel, Pemetrexed Disodium, Aldesleukin, Carboplatin, Cisplatin, Durvalumab, Interleukin-2, Mesna.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IOVA holds $397.5M in cash and short-term investments (as of Sep 30, 2026) and burns about $32.7M/quarter from operations, an estimated runway of 36.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 32 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IOVA files for a raise →

👥 Who Owns IOVA

Insiders 0.3% Institutions (428 holders) 69.2% Public and other holders 30.5%
HolderTypeShares% of sharesAs of
BlackRock, Inc. Institution (13G, 5%+) 33,366,587 7.21% 2026-06-30
MHR Fund Management, LLC Institution (13F) 28,967,103 6.26% 2026-09-30
State Street Corporation Institution (13F) 21,695,003 4.69% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 18,396,706 3.98% 2026-09-30
Two Sigma Investments, LP Institution (13F) 14,964,996 3.23% 2026-09-30
Vanguard Portfolio Management LLC Institution (13F) 12,279,882 2.65% 2026-09-30
Geode Capital Management, LLC Institution (13F) 10,452,242 2.26% 2026-09-30
Shaw D.E. & Co., Inc. Institution (13F) 9,163,428 1.98% 2026-09-30
Dimensional Fund Advisors LP Institution (13F) 6,238,693 1.35% 2026-09-30
Frederick G Vogt
Interim CEO & General Counsel, Director · +93,756 options
Insider 604,144 0.13% 2026-11-11
Raj K. Puri
Chief Regulatory Officer · +58,599 options
Insider 256,364 0.06% 2026-09-08
Daniel Gordon Kirby
Chief Commercial Officer · +50,003 options
Insider 160,576 0.03% 2026-11-10

Share count 462,655,151 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-11-11
filed 2026-11-13
Vogt Frederick G
Option exercise (M) 200,000 $7.55 795,447
2026-11-11
filed 2026-11-13
Vogt Frederick G
Tax withholding (F) 191,303 $8.09 604,144
2026-11-11
filed 2026-11-13
Vogt Frederick G
Option exercise (M) 200,000 – –
2026-11-10
filed 2026-11-12
Kirby Daniel Gordon
Option exercise (M) 10,000 – 164,511
2026-11-10
filed 2026-11-12
Kirby Daniel Gordon
Tax withholding (F) 3,935 $8.08 160,576

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full IOVA picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IOVA and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.